Alternative splicing of tau exon 10 produces tau isoforms with either 3 (3R) or 4 (4R) repeated microtubule-binding domains. Increased ratios of 4R to 3R tau expression, above the physiological 1:1, leads to neurofibrillary tangles and causes neurodegenerative disease. An RNA stem loop structure plays a significant role in determining the ratio, with decreasing stability correlating with an increase in 4R tau mRNA expression. Recent studies have shown that aminoglycosides are able to bind and stabilize the tau stem loop in vitro, suggesting that other druglike small molecules could be identified and that such molecules might lead to decreased exon 10 splicing in vivo. The authors have developed a fluorescent high-throughput fluorescent binding assay and screened a library of ∼110,000 compounds to identify candidate drugs that will bind the tau stem loop in vitro. In addition, they have developed a fluorescent-based RNA probe to assay the stabilizing effects of candiate drugs on the tau stem loop RNA. These assays should be applicable to the general problem of identifying small molecules that interact with mRNA secondary structures. (Journal of Biomolecular Screening 2007:789-799) 
INTRODUCTION
T AUOPATHIES are neurodegenerative disorders characterized by neurofibrillary tangles, intraneuronal masses of paired helical filaments that are composed of highly phosphorylated forms of the microtubule-associated protein tau. 1 Taucontaining neurofibrillary tangles are a common feature in a number of neurodegenerative diseases, including Alzheimer disease, Creutzfeldt-Jakob disease, Pick disease, progressive supranuclear palsy, frontal temporal dementia, and dementia pugilistical. 1 Six protein isoforms are generated through the alternative splicing of the 16 exons encoding the tau gene. [2] [3] [4] Tau stabilizes microtubules through C-terminal microtubule-binding domains encoded by exons 9 through 12. 5 Alternative splicing of exon 10 produces tau isoforms with either 3 (exon 10 missing) or 4 (exon 10 present) repeat domains, known as 3R and 4R tau, respectively. In the adult human brain, the overall ratio of 3R to 4R tau is generally 1.
Mutations in tau itself causes frontotemporal dementia and parkinsonism linked to chromosome 17 (FTD-17). 6 More than 32 such mutations have been identified to date. 7 Among these, 3 are silent mutations in exon 10 (synonymous changes in the nucleotide sequence that do not change the coding of the protein and therefore have no effect on protein function) and 7 are found in the intron following exon 10. All of these mutations in the exon/intron junction alter the 4R-to-3R ratio, implicating impaired splicing as the mechanism of pathogenesis. Most of the silent mutations occur in an RNA stem loop structure that encompasses this junction ( Fig. 1A) , 8 and all of them result in disruption of complementarity and destabilization of this structure. As a consequence of destabilization, this region of the mRNA becomes more available for interaction with the U1 small nuclear ribonucleoprotein (snRNP), resulting in increased splicing of exon 10. Exontrapping studies have clearly shown that intronic mutations increase exon 10 splicing to the degree to which the mutations destabilize the stem loop. 6, 9 We have recently shown that stem loop variants that increase the stability of the stem loop result in decreased inclusion of exon 10 and increased expression of 3R tau. 10 These studies clearly demonstrate that the stability of the stem loop is a significant determinant regulating the ratio of 4R to 3R tau expression. In diseases such as FTD-17, in which the ratio of tau splicing has shifted to 4R tau expression, stabilization of this stem loop that shifts the ratio back toward the 1:1 ratio observed in the normal brain would be expected to be therapeutic. The aminoglycoside neomycin is able to bind and stabilize the tau stem loop in vitro, 11 suggesting that druglike small molecules can be developed to regulate tau mRNA splicing. Aminoglycosides bind to RNA via electrostatic interactions, resulting in weak and poorly specific binding. We have developed a high-throughput strategy to identify other small molecules that can bind and stabilize the tau stem loop with higher affinity and specificity.
The potential for regulating gene expression through the modulation of alternative splicing and translation by the binding of small molecules directly to the mRNA is vast. The success of antisense and small interfering RNAs provides substantial evidence that regulating gene expression at the mRNA level is very powerful. 12 These oligonucleotide-based methods are, however, limited in that they are restricted to downregulating expression and are difficult to deliver to cells. For these reasons, there is substantial interest in identifying small-molecule ligands of mRNA, [13] [14] [15] yet there are no examples of engineered small molecules targeting endogenous mRNA sequences. A greater understanding of the rules that govern these interactions is needed to fully pursue these molecules. 15 The assays developed here may be applicable to the general problem of finding mRNA-binding agents and provide insight into the molecular features involved in binding mRNA structures.
METHODS

TFN and TFT synthesis
Pyrene-neomycin conjugate ( Fig. 1B) was synthesized ( Fig.  1D ) using the following literature procedures. Compound 3 was prepared as described by Tor and coworkers. 16, 17 The amino groups of neomycin (1) were protected as tert-butylcarbamates to give 2. 16 The 5′-OH was converted into 2,4,6-triisopropylbenzenesulfonyl ester, 16 which was treated with aminoethanethiol 17 to give 3. Pyrene carboxylic acid was activated as hydroxysuccinimide ester and coupled with 3 as previously described. 18 Finally, the Boc protecting groups were removed with HCl/dioxane as described 19 to give crude TFN, which was purified by reverse-phase high-performance liquid chromatography (HPLC) using a Discovery ® BIO Wide Pore C18 column (10 × 250 mm, 5 µm) kept at 30 °C using a linear gradient of acetonitrile (10%-40% in 30 min) in 0.1% trifluoroacetic acid buffer at a flow rate of 5 mL/min. Fractions containing pure TFN (retention time = 16.5 min) were evaporated, dissolved in pure water, and freeze dried. Nuclear magnetic resonance (NMR) was performed on these samples to confirm the synthesis product: 1 
RNA binding assays
Binding assays were carried out under buffer conditions similar to those previously described for ultraviolet (UV) melting assays. 9,10 For K d studies, 25 nM TFN or TFT was incubated for 15 min with increasing concentrations of synthetic (Dharmacon) wild-type (WT) tau stem loop RNA, (5′GGCAGUGUGA-GUACCUUCACACGUC3′) in 150 mM NaCl, 10 mM NaPO 4 (pH 6.7), 0.1 mM EDTA. Pyrene fluorescence at 400 nM was then measured after excitation at 340 nM. Binding studies performed subsequent to the screen optimization were done with the addition of 0.04% Nonidet P-40 (NP-40). K d values were calculated from curve fitting of the resulting data using the GraphPad Prism software package. LDN-13978 binding studies were done with both WT and DDPAC mutated (5′GGCAGUGUGAGUACCUU-CAUACGU3′) RNAs.
High-throughput screen
The high-throughput screen (HTS) was carried out using a Beckman Sagian Core system consisting of a Biomek FX pipette station, plate carousel, and a plate shaker. Plates were read using an EnVision multilabel reader from Perkin Elmer integrated with the Beckman Sagian Core system. The compound library is a compilation of several commercially available libraries including drugs approved by the Food and Drug Administration; purified compounds from natural sources; end-blocked tetra peptides; small molecules purchased from Peakdale (High Peak, UK), Maybridge Plc. (Cornwall, UK), Cerep (Paris, France), Bionet Research Ltd. (Cornwall, UK), Prestwick (Ilkirch, France), Specs and Biospecs (CP Rijswijk, the Netherlands), Chemical Diversity Lav (San Diego, CA); and small molecules from different academic institutions. Compounds were preplated 0.4 µL/well from a 125-µM stock solution into black 384-well Greiner plates. Control wells were preplated with 0.4 µL of DMSO. Four sets of controls in 8 wells/control were incorporated in each plate; these included DMSO alone, 25 nM TFN, quenched TFN (prebound 50 nM WT RNA with 25 nM TFN, final concentration) and a positive control. First, 40 µL/well of RNA binding buffer (150 mM NaCl, 10 mM NaPO 4 [pH 6.7], 0.1 mM EDTA, and 0.05% NP-40) was added to each well, and a background fluorescence measurement (excitation at 350 nm, emission at 400 nm) was made. Then, 10 µL of prebound 250 nM WT and 125 nM TFN (50 nM WT and 25 nM TFN, final concentration) was added to each well and incubated for 15 min at room temperature. Fluorescence was then measured again. Overall, 330 plates containing ∼110,000 compounds were screened in this manner over 8 days, with a maximum throughput of ∼25,000 compounds/d.
The Z′ factor, 20 a dimensionless statistic that takes into account the standard deviation (SD) of the positive and negative controls on each plate, was calculated with Excel software using the following equation:
where SD Pos.Control and mean Pos.Control are the SD and mean of (n = 8) positive control wells and SD Quenched and mean Quenched are the SD and mean of (n = 8) wells of prebound RNA/TFN complex.
Data analysis occurs in several steps. First, for filtering purposes, the fold above background (FAB) is calculated for each well:
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where F read1 is the fluorescence from the 1st read and the mean DMSO is the mean of (n = 8) wells of DMSO with buffer alone. Then, the background for each well was subtracted:
where F read1 is the fluorescence from the 1st read and F read2 is the fluorescence from the 2nd read. The percentage of maximum pyrene signal (%MAX) is then calculated for each well:
where the mean TFN-BKGSUB is the mean F BKGSUB of (n = 8) wells with 25 nM TFN with DMSO. The data were filtered by limiting the data set to wells with FAB ≤5 and the %MAX ≥50%.
RNA stability assay
The WT tau and DDPAC tau RNA sequences were synthesized by Dharmacon with a 5′ linked dabsyl and 3′ linked fluorescein generating wild-type RNA labeled with dabscyl and fluorescein (WT-DF) and DDPAC-DF. The WT-DF RNA, treated with increasing concentrations of either a 2′-O-methyl antisense RNA with a phosphorothioate backbone (5′ UGAAG-GUACUCACACUGCCGC 3′) or a randomized control RNA was heated to 95 °C for 1 min and then slowly cooled to 25 °C. Fluorescence was then measured using a PerkinElmer Victor II. In 96-well plates, RNA at a concentration of 50 nM (in the same buffer as the RNA binding assay, see above), was slowly ramped from 30 °C to 90 °C at a rate of 2.75 °/min using a real-time PCR instrument, the ABI 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Ramping was repeated 3 times during each experiment. The fluorescent signal at 535 nm was collected continuously during this heating, generating ∼450 data points per ramp. The data set for each well was normalized by setting the lowest value to 0 and the highest value to 1. These data were then fit with the sigmoidal curve-fitting equation
in the GraphPad Prism software package to calculate the T m of each RNA. T m values from each of the 3 ramps were averaged, and the standard deviations were calculated.
RESULTS
In vitro RNA binding assay
Aminoglycosides are a class of antibiotics that function by binding to ribosomal RNA and interfering with translation. These compounds bind to RNA via electrostatic interactions between the positively charged amine groups on the aminoglycoside and the negatively charged phosphate backbone of the RNA. A recent study demonstrated that the fluorescent moiety pyrene when conjugated to the aminoglycoside paromomycin could act as a fluorescent probe for binding to the 16S ribosomal RNA. 18 When this compound is bound to RNA, the pyrene moiety intercalates into the helix of the RNA, quenching the pyrene fluorescence by the nucleotides that make up the RNA structure. Competition by increasing concentrations of unlabeled paromomycin results in the release of the conjugate and a dose-dependent increase in fluorescence.
We have adapted this intercalating feature of pyrene for a binding assay with the 25-nucleotide stem loop in the tau mRNA ( Fig. 1A) because the aminoglycoside neomycin had previously been shown to bind to the tau stem loop in vitro. 11 We chose to synthesize a pyrene-neomycin conjugate (TFN; Fig. 1B) . Inspection of the NMR structure 11 of neomycin complexed with the tau RNA stem loop suggested that the primary 5′-OH group of ring III (see 1 in Fig. 1D ) might be an accessible site for attachment of the pyrene. Substitution at the 5′-OH was not expected to create any steric clashes or disrupt important noncovalent interactions in the neomycin-RNA complex. 11 Several previous studies 17, [21] [22] [23] [24] have used the 5′-OH as the conjugation site; because this is the only primary hydroxyl in neomycin, it can be derivatized using relatively straightforward chemistry. After protection of all amino groups of the neomycin, nucleophilic displacement at the 5′-OH of 2 (Fig. 1D ) as previously described 16, 17 introduced a short linker with a terminal primary amino group in 3. Earlier studies 18 had shown that, among several pyrene derivatives, pyrenecarboxylic acid when conjugated to paromomycin and tobramycin exhibited the least nonspecific binding to RNA. Therefore, pyrenecarboxylic acid was chosen as the fluorescent label in the present study. The free amino group of 3 was coupled with the pyrenecarboxylic acid, 18 all Boc-protecting groups were removed, 22 and the final pyrene-neomycin conjugate, TFN ( Fig.  1B) , was purified by HPLC. In addition, we synthesized a pyrenetobramycin conjugate, TFT (Fig. 1C) , as previously described. 18
Optimization of binding assay
Initially, we performed a serial dilution of the TFN and TFT to determine the minimum concentration at which the fluorescent signal was linear ( Fig. 2A) . Minimizing the amount of probe included in the reaction was important because this would dictate the amount of RNA needed to quench most of the pyrene fluorescence. The more pyrene needed for a linear signal, the more RNA the assay would require. We found that 25 nM for both conjugates was within the linear range. In the presence of increasing concentrations of RNA, we determined that TFN at 25 nM was able to bind to the tau stem loop RNA (Fig. 2B) with a K d of 17.0 ± 2.6 nM, whereas TFT bound significantly weaker (K d of 170.8 ± 83.4 nM). At the highest concentrations, the fluorescence was quenched to ∼95% in both cases (Fig. 2B) . At WT RNA concentrations of 50 nM, TFN was quenched 88% and TFT was quenched 25%; 515 nM RNA was needed to quench TFT to 90%. We then tested whether the binding of TFN could be competed off the RNA by a known ligand. Neomycin was able to increase fluorescence in a dosedependent manner (Fig. 2C) because of the release of TFN. Therefore, we have developed a fluorescent probe for binding to the tau stem loop RNA that provides a positive fluorescent signal when a ligand binds. For the HTS, we used TFN as a probe because it required significantly less RNA to achieve a low background fluorescence signal. In addition, the high affinity TFN has for the tau mRNA would increase the likelihood that a specific high-affinity compound would be identified.
Optimization of the binding assay for HTS
For screening, we miniaturized this reaction to a 384-well plate format. The binding assay is readily amenable to miniaturization. Briefly, 0.4 µL of 125 µM (a final concentration of 1 µM) compound was preplated into a well, a robotic workstation added 40 µL of buffer (150 mM NaCl, 10 mM NaPO 4 , 0.1 mM EDTA) into each well, and a background fluorescence measurement was made. Tau stem loop RNA and TFN are prebound at 5× concentration (250 nM and 125 nM, respectively). Under these conditions, the RNA quenches the pyrene ∼88% in the absence of competitor. After the preread of the plate, 10 µL of the RNA-TFN complex (50 nM RNA and 25 nM TFN, final concentration) is added to each well and incubated for 15 min at room temperature, at which time the plate is read for a 2nd time. Initial testing of the binding assay under these conditions produced a Z′ factor 20 of 0.5 ± 0.1 and a coefficient of variation (CV) of 7.3% ± 1.3% using 1 mM of G418 as a positive control. We hypothesized that these suboptimal values resulted from the poor meniscus formation in the well. Thus, we tested whether adding detergent would result in a better meniscus formation without interfering with the binding assay. The interaction between the TFN and RNA is in part electrostatic; for this reason, we selected a nonionic detergent NP-40. NP-40 concentrations from 0.005% to 5% were tested. We found that a concentration of 0.04% did not interfere with the binding assay while producing significantly better Z′ factor (0.85 ± 0.06) and CV (3.1% ± 1.4%) values. We proceeded to screen ∼110,000 compounds using a buffer composed of 150 mM NaCl, 10 mM NaPO 4 (pH 6.7), 0.1 mM EDTA, and 0.04% NP-40. These conditions produced an average Z′ factor of 0.79 ± 0.08 over the 330 plates screened (Fig. 3A) .
Data analysis
A significant number of compounds are intrinsically fluorescent under the conditions in which we measured the pyrene fluorescence. Therefore, 40 µL of buffer alone was initially added to each well preplated with 0.4 µL of 125 µM of compound, and the fluorescence was read. Then 10 µL of the prebound TFN-RNA complex was added to each well. Plates were incubated for 15 min and then read again. On average during the screen, it took 32 min between the 1st read and the 2nd read. The fluorescence in the 1st plate read was used as a background subtraction from the 2nd data set collected. If any well had a signal greater than 5 times the background fluorescence in the 1st read, it was no longer considered in the final calculation. Fluorescent signal in each well is calculated as a percentage of the signal that 25 nM TFN alone produces. Prior to applying the filter, a substantial number of compounds displayed a strong signal (Fig. 3B) ; however, using the background subtraction, ∼12% of the compounds were discarded (Fig. 3C) . Using these stringent criteria, we set a threshold of 50% of maximum pyrene signal and identified 92 compounds for validation.
Dose dependence
To validate that the signal detected in the HTS is the result of competition between TFN and the ligand, dose-dependent competition curves were generated using the same RNA binding assay used in the HTS, and EC 50 values were calculated. Initially, we evaluated the identified hits in dose-dependent curves from 0.3 µM to 16 µM with TFN as a probe to confirm the hits from the screen. Dose-dependent data were filtered as described above. If the background value was greater than 5 times the background of buffer alone, then these data points were filtered out. Using these criteria, 22 of the 92 compounds were discarded. Of the remaining 70 compounds, only 1, LDN-13978, displayed dose dependence over these concentrations (Fig. 4) . One reason for the low validation rate in this assay is the possibility of RNase contamination. The quenching of TFN fluorescence depends on the intercalation of the pyrene moiety into the secondary structure of the tau stem loop RNA. If the RNA target is degraded by RNases, TFN would be released, leading to increased fluorescence. In control experiments with serial dilutions of an RNaseA/T1 cocktail (stock concentration of 500 U/mL and 20,000 U/mL, respectively), even extremely low concentrations (>100,000 fold dilution) resulted in 68% ± 5% of the maximum signal (data not shown).
In addition to binding assays done with TFN as a probe, we used the pyrene-tobramycin (Fig. 1C) described above. TFT binds and is quenched in the presence of the tau stem loop; however, it binds with a K d of 170.8 nM, nearly 10 times weaker than TFN binds to the tau stem loop (Fig. 2B) . Because TFT binds more weakly, competition by the ligand takes place more easily. We then confirmed this dose dependence using binding assays with both the TFT and TFN probes over concentrations of 0.5 pM to 5 µM of LDN-13978. In an assay with 50 nM tau stem loop RNA, LDN-13978 had a EC 50 of 714 ± 91.7 nM and 46.9 ± 12.9 nM when competing with 25 nM TFN and TFT, respectively, indicating that LDN-13978 was truly competing for binding with the pyrene conjugates. 
Stem loop stability assay
The ultimate goal of this screen is to identify druglike compounds that not only bind to the tau stem loop RNA but also stabilize the structure. FTD-17 mutations destabilize the tau stem loop in vivo, resulting in greater accessibility to the splice site by the U1 snRNP, which then leads to increased inclusion of exon 10. In 2 previously published reports, 9, 10 we and others demonstrated that the T m of the WT tau stem loop RNA is 70 °C when calculated from UV melting curves. The same studies showed that an FTD-17 mutation destabilizes the stem loop structure and reduces the T m from 70 °C to 55 °C. This mutation, DDPAC, is a C to T change at the +14 of the tau stem loop relative to the exon-intron junction. For the stem loop stability studies, we wanted to address the effect of LDN-13978 binding on the T m of both WT and DDPAC mutated stem loops. First, however, RNA binding studies with WT and DDPAC RNA with the LDN-13978 compound demonstrated that LDN-13978 had similar binding characteristics with both RNAs in the RNA binding assay (Fig. 5A) .
We developed a fluorescent RNA stability assay to evaluate the effect compound binding had on the stability of the RNA. The stability assay uses RNA (WT-DF) identical in nucleotide composition to that used in the binding studies but with 5′ and 3′ modifications. A quencher, dabsyl, is covalently linked to the 5′ end of the RNA, and a fluorophore, fluorescein, is linked to the 3′ end. When the RNA is folded, the 5′ and 3′ ends of the RNA are in close enough proximity that the dabsyl quenches the fluorescence emitted from the fluorescein when it is excited (Fig. 5B) . As the RNA is slowly denatured and unfolds, the dabsyl is no longer able to quench the fluorescein, and increasing fluorescence is measured with increasing temperature. To test that increased fluorescence was a reporter for the unfolding of the WT-DF RNA, we incubated WT-DF at a concentration of 50 nM with increasing concentrations of a previously described antisense RNA that is complementary to the 1st 20 nucleotides of WT-DF or a randomized RNA. Increasing concentrations of antisense RNA resulted in increased fluorescence, whereas the increasing concentrations of the random RNA did not result in increased fluorescence at 535 nm (Fig. 5C) . This assay was optimized for a 96-well plate format using an ABI 7700. The tau stem loop RNA at a concentration of 50 nM in the same buffer as the RNA binding assay is slowly ramped from 30 °C to 90 °C at a rate of 2.75 °/min, resulting in a temperaturedependent increase in fluorescence at 535 nM (Fig. 5D) . This ramp is repeated 3 times during each experiment, and data were collected continuously during this heating, generating ∼450 data points per ramp. The resulting data displayed a sigmoidal curve at 535 nm, transitioning from fully natured at 30 °C to fully denatured at 85 °C (Fig. 5D, inset) .
WT-DF and DDPAC-DF RNAs were ramped from 30 °C to 85 °C in RNA binding buffer. Raw fluorescence data were plotted as a fraction of fluorescence at 85 °C versus temperature. Using a sigmoidal fit to the data, the temperature at the midpoint of the transition is calculated; this is the melting temperature, T m , of the RNA. The T m values generated using this method for the WT-DF and DDPAC-DF RNAs were 67.49 °C ± 1.22 °C and 53.17 °C ± 0.75 °C, respectively, nearly identical to those measured in a previously published report using UV melting curves (Fig. 6A) . 9, 11 In addition, UV melting curves and fluorescent melting curves were indistinguishable from each other (data not shown), suggesting that the thermodynamics of unfolding are similar in both assays.
Compounds that stabilize the stem loop RNA shift the melting curve of the RNA, resulting in a higher T m measurement. The stabilization of the stem loop RNAs in the presence of compounds is the result of both the affinity of the compound for the RNA as well as the stabilizing nature of the compound. In general, compounds that have higher affinity for the RNA should be more stabilizing. WT-DF and DDPAC-DF RNAs were ramped from 30 °C to 90 °C in RNA binding buffer with increasing concentrations of LDN-13978. At concentrations as low as 800 nM, LDN-13978 increased measured T m s for both WT-DF and DDPAC-DF ( Fig. 6B-6C) . Thus, LDN-13978 binds and stabilizes the tau stem loop RNAs. One concern with this assay is the stability of compounds at the high temperatures used in the melting assay. During each measurement, data are collected from 3 consecutive ramps. If the compound is degrading, then it might display decreasing stabilization with each successive ramp. In the case of LDN-13978, the CV for the As the RNA is denatured, the dabsyl is no longer in close enough proximity to quench the fluorescence from fluorescein, resulting in increasing fluorescence with increased denaturation. (C) Antisense RNA was used to test that the denaturation of wild-type RNA labeled with dabscyl and fluorescein (WT-DF) RNA resulted in an increase in fluorescence at 535 nm. A plot is shown here demonstrating that increasing concentrations of antisense RNA directed against the tau stem loop RNA results in a dose-dependent increase in fluorescence, whereas a randomized RNA does not. (D) Fluorescent emission of fluorescein peaks at 535 nM. Plotting the fluorescent signal from WT-DF RNA over a spectrum of 500 to 650 nM shows that the amplitude of this peak increases with increasing temperature. The inset graph represents the sigmoidal plot of signal at 535 nM versus temperature.
3 ramps averaged 0.21% ± 0.05% indicating that there was no loss of LDN-13978 activity during the assay.
DISCUSSION
Targeting RNA as a general therapeutic is in its infancy, but the importance of this approach is becoming ever clearer. 14, 25 RNA folds into secondary and tertiary structures with the complexity observed in proteins, resulting in binding sites amenable to docking by small molecules. Increasing evidence suggests that alternative splicing of mRNAs is regulated in large part either directly by RNA structures or by protein factors that bind to these structures within the mRNA. 26 These regulatory RNA elements would be ideal drug targets for modulating disease-causing splicing events. In prokaryotes, there are examples of naturally evolved small-molecule mRNA binding interactions: Riboswitches, structural mRNA elements found in the untranslated regions, bind metabolites to regulate transcription and translation. 27, 28 The existence of riboswitches proves that small molecules can target mRNA.
We hypothesize that the regulatory RNA stem loop found at the 3′ end of exon 10 of the tau mRNA represents a target structure for therapeutic small molecules in the treatment of FTD-17 and Alzheimer disease. Toward this end, we have developed an HTS to specifically identify druglike compounds that not only bind to the RNA stem loop but also increase the thermal stability of this structure. A screen of ∼110,000 compounds using these assays yielded a validated compound, LDN-13978. Interestingly, LDN-13978 is among a class of compounds known as intercalators, compounds that bind to DNA via intercalation into helical DNA structures. Intercalators are among the classes of molecules we expected to find in this screen, further validating that the HTS identified a viable lead compound. Several other commercially available intercalators were tested in the in vitro binding and stabilization assays. Of the 11 compounds tested, only 1 showed even modest activity (data not shown). These results strongly suggest that chemical features of LDN-13978, other than the intercalating moiety, are the basis for the affinity LDN-13978 has for the tau stem loop RNA. We plan to use the assays developed here to enhance affinity, specificity, and stabilizing activity of LDN-13978 via analogue design and synthesis. The stability assay in particular will be essential to ranking the activity of the chemically modified analogs. Unlike the competition assay, the stability assay evaluates directly the interaction between the RNA ligand and the compound. Although the assays developed here would be easily transferable to the identification of small-molecule binding partners to other mRNA targets, there are a few details that warrant careful attention when designing such assays. First, we identified only 1 validated hit in this screen. This is likely the result of using a highaffinity probe (K d of 17 nM) in the competition binding assay. To be identified as a hit, a compound had to have a minimum EC 50 of 1 µM, translating to a compound with nM affinity for the RNA to remain in the data set after the filter. In addition, because this assay relies on the displacement of TFN bound to the RNA, only compounds that share the same binding site yield a positive signal. This assay would miss compounds that bind to an alternative site. Although unlikely in this particular screen (because we used a small [25-nucleotide] RNA target), this is an important consideration when designing assays against larger, more complex RNA targets. Second, the screen yielded 92 initial hits with only 1 validated hit. High background fluorescence for 22 of these compounds was the likely reason for their identification in the screen. It was essential to preread the plates after buffer addition to quantitate the fluorescent nature of the compounds in the library. We discarded 12% of the compounds in the library from our data analysis. Finally, special attention needs to be paid to ensure that RNase contamination is minimized during screening. In this assay, degradation of the tau stem loop would lead to an increase in unquenched TFN and pyrene fluorescence, resulting in a false positive. It is likely that the reason for our low validation rate of the remaining 70 positive hits was RNase contamination.
Alternative splicing is a significant contributor to protein diversity, with estimates that 75% of human genes are alternatively spliced, with tissue-specific splicing being highest in the brain. 29, 30 In addition, it is estimated that some 15% of genetic defects in humans are caused by point mutations that manifest themselves as pre-mRNA splicing defects through changes in splice site sequences. 29, 31 Most important, alternative splicing is emerging as a major factor in the regulation of protein function and gene expression. 32 Thus, the development of a general strategy toward the discovery of small molecules that modulate specific splicing events would have broad implications for biology and medicine.
